Ananthakrishnan Sankaranarayanan

Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases

Christine Beeton, Heike Wulff, Nathan Standifer et al. · Proceedings of the National Academy of Sciences · 2006 · 525 citations · Full text

T-regulatory Cell, Immunology, Immune Regulation +18

Design of PAP-1, a Selective Small Molecule Kv1.3 Blocker, for the Suppression of Effector Memory T Cells in Autoimmune Diseases

Alexander Schmitz, Ananthakrishnan Sankaranarayanan, Philippe Azam et al. · Molecular Pharmacology · 2005 · 219 citations

Early Changes in Cerebellar Physiology Accompany Motor Dysfunction in the Polyglutamine Disease Spinocerebellar Ataxia Type 3

Vikram G. Shakkottai, Maria do Carmo Costa, James Dell’Orco et al. · Journal of Neuroscience · 2011 · 214 citations · Full text

Early Changes, Neurological Disorder, Motor Control +17

Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a New Activator of KCa2 and KCa3.1 Potassium Channels, Potentiates the Endothelium-Derived Hyperpolarizing Factor Response and Lowers Blood Pressure

Ananthakrishnan Sankaranarayanan, Girija Raman, Christoph Busch et al. · Molecular Pharmacology · 2008 · 207 citations · Full text

Targeting Effector Memory T Cells with the Small Molecule Kv1.3 Blocker PAP-1 Suppresses Allergic Contact Dermatitis

Philippe Azam, Ananthakrishnan Sankaranarayanan, Daniel Homerick et al. · Journal of Investigative Dermatology · 2007 · 95 citations · Full text

Signal Transduction, Allergy, T-regulatory Cell +8